Thrombolysis in myocardial infarction ( TIMI ) flow , creatine kinase MB isoenzyme ( CK-MB ) levels , acute thrombus events , efficacy and safety endpoints at Day 7 , Day 30 , 6 months and 1 year ( efficacy endpoints : death , myocardial infarction , target vessel revascularization and ischemic stroke ; safety endpoints : bleeding and thrombocytopenia ) were observed and compared between the two groups .